In addition, MEK1/2 (MAP kinase-Erk-kinase 1 and 2) inhibition has proven quite efficacious in pediatric low-grade gliomas, suggesting that it is feasible to safely target the MEK pathway in children with brain tumors without excessive toxicity [22]. This evidence concerns the gene MAP2K1 and glioma.